Visium Asset Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Visium Asset Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-150,000	Closed	-$1.87M	–	1252
2014 Q3	$1.87M	Hold	150,000	–	–	0.03%	481
2014 Q2	$2.2M	Hold	150,000	–	–	0.03%	391
2014 Q1	$3.05M	Hold	150,000	–	–	0.05%	310
2013 Q4	$2.94M	Hold	150,000	–	–	0.06%	278
2013 Q3	$6.79M	Sell	150,000 -150,000	-50%	-$4.89M	0.15%	110
2013 Q2	$7.15M	Buy	+300,000	New	+$4.78M	0.17%	95

Other funds holding STML

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Visium Asset Management's STML Position: Q4 2014 in Review

Visium Asset Management sold out of Stemline Therapeutics, Inc. (STML) in Q4 2014, closing a stake of 150,000 shares — an estimated $1.87M sold.

Visium Asset Management first reported a position in STML in Q2 2013 and held it in 6 quarters. The position peaked at $7.15M in Q2 2013. 62 funds tracked by Wall St. Rank hold STML as of Q4 2014.

Visium Asset Management reported no remaining Stemline Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
Visium Asset Management sold 150,000 Stemline Therapeutics, Inc. shares in Q4 2014, an estimated $1.87M.
Visium Asset Management first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 6 quarters.
Visium Asset Management's Stemline Therapeutics, Inc. position peaked at $7.15M in Q2 2013.
62 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2014.

Based on Visium Asset Management's 13F filing for Q4 2014, filed 13 Feb 2015.